<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03447379</url>
  </required_header>
  <id_info>
    <org_study_id>3-2017-0230</org_study_id>
    <nct_id>NCT03447379</nct_id>
  </id_info>
  <brief_title>Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent</brief_title>
  <official_title>Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;•Prospective, open label, randomized, multicenter study&#xD;
&#xD;
        -  Patients treated with a new generation of Everolimus-eluting stents (Synergy®). After&#xD;
           PTCA, patients are randomized to a group of DAPT for one year or a group of P2Y12&#xD;
           monotherapy after 3 months of DAPT. After 12 months of PTCA, evaluate major&#xD;
           cardiovascular events and major bleeding events&#xD;
&#xD;
        -  This study is to confirm after PTCA, DAPT for three months is not considered to be&#xD;
           inferior to keeping DAPT for a year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular clinical events (MACCE)</measure>
    <time_frame>between 3 and 12 month after the procedure</time_frame>
    <description>cardiovascular-related death, myocardial infarction, stent thrombosis, stroke, or target lesion revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>between 3 and 12 month after the procedure</time_frame>
    <description>The Bleeding Academic Research Consortium (BARC) type 3 or 5</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1452</enrollment>
  <condition>Coronary Artery Occlusive Disease</condition>
  <arm_group>
    <arm_group_label>P2Y12 monotherapy after 3 months of DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual-antiplatelet therapy for a year</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day) for a year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1. P2Y12 inhibitor monotherapy after 3 months of DAPT</intervention_name>
    <description>P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day)&#xD;
DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day) for a year</description>
    <arm_group_label>Dual-antiplatelet therapy for a year</arm_group_label>
    <arm_group_label>P2Y12 monotherapy after 3 months of DAPT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 19+&#xD;
&#xD;
          2. Patients treated with a new generation of Evelorimus-eluting stents (Synergy®)&#xD;
&#xD;
          3. Patients who understand the content of the subject description and voluntarily sign&#xD;
             the subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age 86+&#xD;
&#xD;
          2. Hemodynamically unstable patient&#xD;
&#xD;
          3. Severe hypersensitivity reactions to aspirin, clopidogrel, ticagrelor, everolimus,&#xD;
             contrast agent&#xD;
&#xD;
          4. Patients at high risk of bleeding, anemia, thrombocytopenia&#xD;
&#xD;
          5. Patients requiring oral anticoagulants&#xD;
&#xD;
          6. Pregnant women or women of childbearing age&#xD;
&#xD;
          7. Life expectancy is less than one year&#xD;
&#xD;
          8. Patients receiving a potent CYP3A4 inhibitor (eg, ketoconazole, clarithromycin,&#xD;
             napjodone, ritonavir, atazanavir)&#xD;
&#xD;
          9. Patients with a history of intracranial hemorrhage&#xD;
&#xD;
         10. Patients with moderate to severe hepatic impairment&#xD;
&#xD;
         11. Patients underwent coronary intervention with stenting within 1 year&#xD;
&#xD;
         12. Patients with left-main lesions requiring coronary intervention&#xD;
&#xD;
         13. Patients with chronic stricture lesions requiring treatment&#xD;
&#xD;
         14. Patients with in-stent restenosis in a lesion requiring treatment&#xD;
&#xD;
         15. Patients with bifurcation lesions requiring stenting in lateral branches&#xD;
&#xD;
         16. Patients with lesions requiring more than 3 stents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bumkee Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Souel</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>March 7, 2021</last_update_submitted>
  <last_update_submitted_qc>March 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Bumkee Hong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

